Zynerba Pharmaceuticals (ZYNE) Given News Impact Rating of 0.10

Media stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.7746680944187 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded up $0.25 during midday trading on Thursday, hitting $11.50. 200,100 shares of the company were exchanged, compared to its average volume of 375,527. The company has a market cap of $155.04 and a P/E ratio of -4.44. Zynerba Pharmaceuticals has a twelve month low of $5.42 and a twelve month high of $25.95.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.05). During the same quarter in the previous year, the firm earned ($0.67) EPS. sell-side analysts predict that Zynerba Pharmaceuticals will post -2.49 earnings per share for the current fiscal year.

Several research firms have recently commented on ZYNE. Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th. Roth Capital set a $15.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 1st. Cantor Fitzgerald set a $17.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Canaccord Genuity set a $18.00 price target on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 4th. Finally, Piper Jaffray Companies increased their price target on shares of Zynerba Pharmaceuticals from $16.00 to $20.00 in a research report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. Zynerba Pharmaceuticals has an average rating of “Hold” and an average target price of $15.00.

In related news, major shareholder Michael Rapp acquired 15,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were purchased at an average cost of $12.99 per share, with a total value of $194,850.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.91% of the company’s stock.

WARNING: “Zynerba Pharmaceuticals (ZYNE) Given News Impact Rating of 0.10” was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3144533/zynerba-pharmaceuticals-zyne-given-news-impact-rating-of-0-10.html.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Insider Buying and Selling by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.